South Korea based
Pharos I&BT Co., Ltd. will develop an intractable rare disease drug, based on the improvement of healthcare platforms through disease and compound big data analysis, which will improve the quality of life of patients suffering from diseases and provide greater happiness.
Drug Discovery and Development Biotech Company specializing in collecting and
analyzing big data based on IT technology.
The company's platform uses artificial intelligence technology to analyze and predict the various properties of targets, compounds, effective substances based on big data, enabling research institutes to develop new drugs effectively.
PHI-101-001 is a treatment drug for refractory/recurrent acute myelogenous leukemia (AML).
It is a ”Best-in-Class” next-generation FLT3 inhibitor with high safety and compared to global competitors and differentiated efficacy against
resistance of existing FLT3 inhibitors. Currently, we are conducting phase 1 global clinical trials in Australia and Korea.
PHI-101-002 was derived from the analysis of indications expansion using Pharos iBio's big data & AI-based new drug development platform.
It is being developed for patients with platinum-resistant/refractory ovarian cancer, and is currently used to evaluate safety,
tolerability and pharmacokinetic properties. Phase 1 clinical trials are in progress in Korea.
PHI-101-003 is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC) through an indication expansion analysis using Pharos iBio's big data & AI-based drug development platform. TNBC has limited adequate targeted treatment, and it relies primarily on chemotherapy. However, since treatment often leads to recurrence and metastasis, the development of a treatment is urgent. PHI-101-003 is expected to be applicable to a variety of solid cancers, not limited to triple-negative breast cancer, through combination therapy based on the excellent anti-cancer effect shown in intermediary studies.
PHI-101-004 is a drug that is being developed as a radiation sensitizer through an indication expansion analysis using Pharos iBio's big data & AI-based new drug development platform. It can be taken at the same time when cancer patients receive radiation therapy to improve the efficiency of radiation treatment to cancer tissues, so that the same effect can be obtained with a small amount of radiation, while reducing damage to normal cells.
The KRAS gene is an important factor that plays an on/off role in cell signaling related to cell differentiation, proliferation, and survival.
When genetic mutation occurs, cells continue to proliferate or fail to control apoptosis, often leading to cancer.
KRAS is a representative oncogene in which more than 30-40% of gene mutations are found in various cancers, but it has been known as an “undruggable” target until now because it is relatively difficult to develop. PHI-201 is being developed as an optimal new drug candidate by using a new drug development platform based on big data & AI.
FAK (Focal Adhesion kinase) plays an important role in signal transduction involved in cell migration, proliferation and differentiation
by regulating cell growth and adhesion to extracellular matrix in normal and tumor cells. It is known that mutation of the FAK gene
causes the loss of the interaction between the cell and the extracellular matrix, leading to metastasis of cancer cells. PHI-301 is a FAK inhibitor and is being developed as a drug to treat metastatic cancer by inhibiting abnormal signal transduction between cells and extracellular matrix.
The oncogene ALK (Anaplastic Lymphoma Kinase) is a representative tyrosine kinase receptor that spans cell membranes, and mutations in this gene have been found in non-small cell lung cancer and other solid cancers in addition to lymphoma. Since then, many types of ALK inhibitors have been developed, but cancer cells induce secondary mutations or use a bypass signaling system to give resistance to ALK inhibitors. PHI-401 is a drug being developed using big data and AI-based platforms to overcome drug resistance, which is the most problematic in the treatment of ALK inhibitors.
RAS, an oncogene, exists in three forms: KRAS, NRAS, and HRAS, and RAS mutations are commonly observed in patients with more than 30% of various cancers. By type, KRAS mutation reaches 83%, NRAS 13%, HRAS 4%, and in particular, mutations of NRAS have been found a lot in hematological cancer and melanoma. Through various pathways such as RAF/MAPK, PI3K/AKT, and MEKK/JNK, it induces cell growth, proliferation and transformation. Pharos iBio is developing next-generation inhibitors with high safety and differential efficacy compared to NRAS global competitors.
No services posted yet